Treatment of atrial fibrillation and flutter: Focus on oral dofetilide, a new selective class III antiarrhythmic agent

HeartDrug

Volumn 1, Issue 6, 2001, Pages 320-331

  Chong, Pang H ^a,b,d,e   Franklin, Cory ^b,c   Yim, Barbara T ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^c ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^d MIDWESTERN UNIVERSITY   (United States)

^e Jr Hospital of Cook County   (United States)

Author keywords

Antiarrhythmic agents; Arrhythmia; Atrial fibrillation; Atrial flutter; Dofetilide; Proarrhythmia

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DISOPYRAMIDE; DOFETILIDE; FLECAINIDE; IBUTILIDE; POTASSIUM CHANNEL; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SODIUM CHANNEL; SOTALOL;

CLINICAL TRIAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART PROARRHYTHMIA; HEART RATE; HEART RHYTHM; HEART VENTRICLE TACHYCARDIA; HUMAN; MAINTENANCE THERAPY; PRIORITY JOURNAL; QT INTERVAL; REVIEW; SINUS RHYTHM; TORSADE DES POINTES;

EID: 0035717897     PISSN: 14229528     EISSN: None     Source Type: Journal    
DOI: 10.1159/000048982     Document Type: Review

References (46)

1. Arrhythmias
2. Reentrant mechanisms underlying atrial fibrillation
3. Genesis of cardiac arrhythmias: Electrophysiological considerations
4. Pharmacologic management of atrial fibrillation: Current therapeutic strategies
5. Management of atrial fibrillation: Therapeutic options and clinical decisions
6. Management of patients with atrial fibrillation. A statement for healthcare professionals from the Subcommittee on Electrocardiography and Electrophysiology
7. Atrial fibrillation
8. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications
9. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study
10. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials
11. Classification of atrial fibrillation
12. A classification of antiarrhythmic actions reassessed after a decade of new drugs
13. Atrial fibrillation follow-up investigation of rhythm management - The AFFIRM study design
14. Rhythm or rate control in atrial fibrillation - Pharmacological Intervention in Atrial Fibrillation (PIAF): A randomized trial
15. Prophylactic drug therapy after cardioversion of atrial fibrillation or flutter
16. Amiodarone to prevent recurrence of atrial fibrillation
17. Proarrhythmia
18. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials
19. Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation
20. Flecainde acetate in atrial flutter and fibrillation. The arrhythmogenic effects
21. Proarrhythmia
22. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation
23. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial
24. Torsade de pointes due to quinidine: Observation in 31 patients
25. Pause-dependent polymorphic ventricular tachycardia during long-term treatment with dofetilide
26. 'Late' proarrhythmia due to quinidine
27. Dofetilide
28. Dofetilide: A new pure class III antriarrhythmic agent
29. Dofetilide in patients with congestive heart failure and left ventricular dysfunction
30. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: A randomized trial
31. Effects of the new class III antiarrhythmic drug dofetilide on the atrial and ventricular intracardiac monophasic action potential in patients with angina pectoris
32. Clinical and electrophysiologic effects of intravenous dofetilide (UK-68,798), a new class III antriarrhythmic drug, in patients with angina pectoris
33. + channels
34. Pharmacokinetic and pharmacodynamic modeling of the effects of oral and intravenous administrations of dofetilide on ventricular repolarization
35. Pharmacodynamics and pharmacokinetics of the class III antiarrhythmic agent dofetilide (UK-68,798) in humans
36. Dofetilide: Is the treatment worse than the disease
37. Dofetilide for atrial fibrillation
38. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: The Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE D) Study
39. Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide. The EMERALD (European and Australian Multicenter Evaluative Research on Atrial Fibrillation Dofetilide) study
40. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function
41. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: Observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT): The Department of Veterans Affairs CHF-STAT Investigators
42. Effect of dofetilide on survival in patients with supraventricular arrhythmias
43. QTc interval as a guide to select those patients with congestive heart failure and reduced left ventricular systolic function who will benefit from antiarrhythmic treatment with dofetilide
44. Practical approaches to treating atrial fibrillation: A roundtable discussion with the experts